Baytril 100 is for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non‑lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy heifers less than 20 months of age at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
BRD has a significant health and economic impact on cattle operations across the country. Particularly susceptible are cattle at high risk of developing infections due to stress from travel and co-mingling with other cattle.
Specific high-risk factors for cattle can include:
- Transportation with animals from two or more farm origins
- Extended transport time with few to no rest stops
- Environmental temperature changes of ≥30°F between locations, within a 24-hour period upon arrival
- Exposure to wet or cold weather conditions
- Excessive shrink (more than would be expected with normal load of cattle)
- Stressful arrival processing procedures, such as castration or dehorning
- Exposure within previous 72 hours to animals showing clinical signs of BRD
“With the approval of Baytril 100 for control of BRD in high-risk cattle, there is greater flexibility for the management of BRD — whether it is a metaphylaxis or treatment scenario,” said Dan Thomson of the Beef Cattle Institute, Kansas State University.
In the lab, Baytril 100 kills 97 percent of the key BRD-causing bacteria in one to two hours, in vitro.* In a clinical field study, Baytril 100 demonstrated statistically significant control of BRD in high-risk cattle in a 14-day study.
Available in 100 mL, 250 mL and 500 mL bottles, Baytril 100 has been a choice for many bovine veterinarians and cattle producers since its introduction in 1998 and is the largest-selling, single-dose antibiotic in its class. The first FDA-approved fluoroquinolone antimicrobial for use against BRD, Baytril 100 is a proven and effective BRD antimicrobial.
*The clinical significance of in vitro data has not been demonstrated.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Extra-label use of this product in food-producing animals is prohibited. Cattle intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. 
—From Bayer HealthCare news release
